Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical factors causing hyponatremia in patients with mucocutaneous lymph node syndrome

가와사끼병에서 저나트륨혈증의 관련인자에 대한 임상적 고찰

  • Kim, Soo Yeon (Department of Pediatrics, Eulji University School of Medicine) ;
  • Kim, Hyun Jung (Department of Pediatrics, Eulji University School of Medicine) ;
  • Choi, Jun Seok (Department of Pediatrics, Eulji University School of Medicine) ;
  • Huh, Jae Kyung (Department of Pediatrics, Eulji University School of Medicine)
  • 김수연 (을지의과대학교 소아과학교실) ;
  • 김현정 (을지의과대학교 소아과학교실) ;
  • 최준석 (을지의과대학교 소아과학교실) ;
  • 허재경 (을지의과대학교 소아과학교실)
  • Received : 2008.08.18
  • Accepted : 2008.11.11
  • Published : 2009.03.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Clinical and laboratory findings predict a severe outcome for mucocutaneous lymph node syndrome. This study aimed to define the clinical characteristics of Kawasaki disease (KD) patients with hyponatremia and to determine the factors associated with its development. Methods : Retrospective studies were performed on 114 KD patients who received an initial high-dose intravenous immunoglobulin (IVIG, single 2 g/kg/dose) within 10 days of fever onset from January 2006 to February 2008. These patients were divided into 2 groups. Group 1 consisted of 30 (26.3%) patients with hyponatremia, and group 2 consisted of 84 (73.6%) patients without hyponatremia. Clinical manifestations, laboratory results, and echocardiographic findings were compared between the groups. Results : Group 1 patients were more likely to have a coronary artery lesion (53.3% versus 20.2%, P=0.005) and suffered from diarrhea (41.3% versus 14.1%, P=0.007). There was a higher incidence of cardiovascular involvement in group 1 patients, including coronary dilatation (46.6%), valvular regurgitation (13.3%), pericardial effusion (6.7%) and medium-sized aneurysm (6.7%). There were no coronary aneurysms in group 2 patients. Serum C-reactive protein (CRP) was significantly higher in patients with hyponatremia ($12.2{\pm}7.79$ mg/dL versus $7.3{\pm}4.7$ mg/dL, P=0.003) and IVIG-resistant patients were more common in group 1 (13.3% versus 3.6%). Conclusion : These results indicate that hyponatremia in KD occurs in patients exhibiting severe inflammation and was significantly associated with the development of coronary disease. Further studies will be necessary to confirm the pathogenic mechanisms of hyponatremia in KD patients.

목 적 : 가와사끼병의 급성기에 심장 합병증을 미리 예측하고자 하는 연구가 꾸준히 계속되고 있으나 아직까지 확실하게 인정되고 있는 지표는 없는 실정이다. 이에 저자들은 저나트륨혈증이 가와사끼병 급성기에 나타나는 빈도와 다른 임상적 요인 및 관상동맥 합병증과의 연관성을 알아보고자 하였다. 방 법 : 2006년 1월부터 2008년 2월까지 만 2년간 을지대학병원 소아과에 입원하여 가와사끼병으로 치료받았던 114명의 환자를 대상으로 후향적으로 조사하였다. 나이와 성별, 발열부터 면역글로불린 투여시까지의 기간, 치료부터 해열까지의 기간, 입원 당시의 백혈구수, 혈소판수,알부민, ESR, CRP, AST, ALT치와 무균성 농뇨 및 심초음파 결과 등을 저나트륨혈증군(1군) (n=30)과 정상 나트륨군(2군) (n=84)으로 나누어 비교 분석하였다. 통계 처리는 t-test와 교차분석, logistic 회귀 분석을 사용하였다. 결 과 : 1) 1군의 환자들에게서 설사 증상이 나타났던 경우가 40%로 2군의 환자들보다 유의하게 많았으며 농뇨나 혈뇨의 빈도는 두 군간에 유의한 차이가 없었다. 2) 1군 환아들에서의 CRP 수치가 평균 12.2 mg/dL로 2군 환아들에서의 7.3 mg/dL에 비하여 유의하게 높았다. 3) 1군에서 13.3%의 환아에서 1회의 IVIG 치료 후에도 발열이 지속되어 IVIG의 재투여가 필요하였으며 2군의 환아들에 비해 3배 가량 많았다. 4) 1군 중 53.3%에서 관상 동맥의 병변이 있었으며 2군의 20.2%에 비해 유의하게 많았으며 1군 중 2명(6.7%)에서 중등도 크기의 관상동맥류가 있었다. 결 론 : 가와사끼병에서 입원 당시에 저나트륨혈증이 있거나 면역글로불린 투여 이후에도 저나트륨혈증이 지속될 때 관상 동맥의 합병증이 더 많이 발생할 가능성을 염두에 두고 치료에 임하는 것이 좋을 것으로 사료되는 바이다.

Keywords

References

  1. Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr 1986; 108:388-92 https://doi.org/10.1016/S0022-3476(86)80878-2
  2. Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol 1998;81:1116-20 https://doi.org/10.1016/S0002-9149(98)00116-7
  3. Koyanagi H, Nakamura Y, Yanagawa H. Lower level of serum potassium and higher level of C-reactive protein as an independent risk factor for giant aneurysms in Kawasaki disease. Acta Paediatr 1998;87:32-6 https://doi.org/10.1080/08035259850157831
  4. Watanabe T, Abe Y, Sato S, Uehara Y, Ikeno K, Abe T. Hyponatremia in Kawasaki disease. Pediatr Nephrol 2006; 21:778-81 https://doi.org/10.1007/s00467-006-0086-6
  5. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006; 149:237-40 https://doi.org/10.1016/j.jpeds.2006.03.050
  6. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12 https://doi.org/10.1161/CIRCULATIONAHA.105.592865
  7. Takahashi M. Kawasaki syndrome (mucocutaneous lymph node syndrome). In: Allen HD, Gutgesell HD, Clark EB, Driscoll DJ, editors. Moss and Adams' heart disease in infants, children, and adolescents including the fetus and young adults. 6th ed. Philadelpia : Lippinocott Williams & Wilkins Co, 2001;1216-25
  8. Dajani AS, Taubert KA, Takahashi M, Bierman FZ, Freed MD, Ferrieri P, et al. Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1994;89:916-22
  9. Research Committee on Kawasaki disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Ministry of Health and Welfare, Tokyo, 1984
  10. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85
  11. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776-80
  12. Asai T. Evaluation method for the degree of seriousness in Kawasaki disease. Acta Paediatr Jpn 1983;25:170-5 https://doi.org/10.1111/j.1442-200X.1983.tb01683.x
  13. Harada K, Yamaguchi H, Kato H. Indication for intravenous gamma globulin treatment for Kawasaki disease. In : Takahashi M, Taubert K, editors. Proceedings of the Fourth International Symposium on Kawasaki disease. American Heart Association, Dallas, 1993:459-62
  14. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1983;25:170-5 https://doi.org/10.1111/j.1442-200X.1983.tb01683.x
  15. Laxer RM, Petty RE. Hyponatremia in Kawasaki disease. Pediatrics 1982;4:655 https://doi.org/10.1007/s00467-006-0086-6
  16. Nakabayashi Y, Shimizu T. Hyponatremia in Kawasaki disease. Nippon Shoni Jinzobyo Gakkai Zasshi 2002;15:83-7 https://doi.org/10.3165/jjpn.15.83
  17. Muta H, Ishii M, Egami K, Hayasaka S, Nakamura Y, Yanagawa H, et al. Serum sodium levels in patients with Kawasaki disease. Pediatr Cardiol 2005;26:404-7 https://doi.org/10.1007/s00246-004-0789-z
  18. Suzuki H, Takeuchi T, Minami T, Shibuta S, Uemura S, Yoshikawa N. Water retention in the acute phase of Kawasaki disease: relationship between oedema and the development of coronary artery lesions. Eur J Pediatr 2003;162:856-9 https://doi.org/10.1007/s00431-003-1326-4
  19. Leung DYM, Meissner HC, Fulton DR, Quimby F, Schlievert PM. Superantigens in Kawasaki syndrome. Clin Immunol Immunopathol 1995;77:119-26 https://doi.org/10.1006/clin.1995.1134
  20. Leung DYM, Chu ET, Wood N, Grady S, Meade R, Geha RS. Immno regulartory T cell abnormalities in mucocutaneous lymph node syndrome. J Immunol 1983;130:2002-4
  21. Ferriero DM, Wolfsdorf JI. Hemolytic uremic syndrome associated with Kawasaki disease. Pediatrics 1981;68:405-6
  22. Rhodes J, King ME, Aretz HT. An 11-year-old girl with fever, hypotension and azotemia. N Engl J Med 1998;339: 1619-26 https://doi.org/10.1056/NEJM199811263392208
  23. Bonany PJ, Bilkis MD, Gallo G, Lago N, Dennehy MV, Sosa del Valle JM, et al. Acute renal failure in typical Kawasaki disease. Pediatr Nephrol 2002;17:329-31 https://doi.org/10.1007/s00467-002-0844-z
  24. Mine K, Takaya J, Hasui M, Ikemoto Y, Teraguchi M, Kobayashi Y. A case of Kawasaki disease associated with syndrome of inappropriate secretion of antidiuretic hormone. Acta Paediatr 2004;93:1547-9 https://doi.org/10.1080/08035250410028002
  25. Ohta K, Seno A, Shintan N, Kato E, Yachie A, Seki H, et al. Increased levels of urinary interleukin-6 in Kawasaki disease. Eur J Pediatr 1993;152:647-9 https://doi.org/10.1007/BF01955240
  26. Jibiki T, Terai M, Kohno Y. High concentrations of interleukin-8 and monocyte chemoattractant protein-1 in urine of patients with acute Kawasaki disease. Eur J Pediatr 2004; 163:749-50 https://doi.org/10.1007/s00431-004-1539-1
  27. Nakamura Y, Yashiro M, Uehara R, Watanabe M, Tajimi M, Oki I, et al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 2004;46:33-8 https://doi.org/10.1111/j.1442-200X.2004.01840.x
  28. Fujiwara T, Fujiwara H, Hamashima Y. Frequency and size of coronary arterial aneurysm at necropsy in Kawasaki disease. Am J Cardiol 1987;59:808-11 https://doi.org/10.1016/0002-9149(87)91096-4
  29. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003; 24:145-8 https://doi.org/10.1007/s00246-002-0216-2
  30. Han RK, Silverman ED, Newman A, McCrindle BW. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med 2000;154:694-9
  31. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998;17:1144-8 https://doi.org/10.1097/00006454-199812000-00009
  32. Jia EZ, Yang ZJ, Zhu TB, Wang LS, Chen B, Cao KJ, et al. Serum sodium concentration is significantly associated with the angiographic characteristics of coronary atherosclerosis. Acta Pharmacol Sin 2007;28:1136-42 https://doi.org/10.1111/j.1745-7254.2007.00597.x
  33. De Luca L, Klein L, Udelson JE, Orlandi C, Sardella G, Fedele F, et al. Hyponatremia in patients with heart failure. Am J Cardiol 2005;96:19-23
  34. Eisenhut M. Changes in renal sodium transport during a systemic inflammatory response. Pediatr Nephrol 2006;21: 1487-8 https://doi.org/10.1007/s00467-006-0199-y
  35. Maeno N, Takei S, Masuda K, Akaike H, Matsuo K, Kitajima I, et al. Increased serum levels of vascular endothelial growth factor in Kawasaki disease. Pediatr Res 1998;44:596- 9 https://doi.org/10.1203/00006450-199810000-00021
  36. Ohno T, Yuge T, Kariyazono H, Igarashi H, Jono K, Kinugawa N, et al. Serum hepatocyte growth factor combined with vascular endothelial growth factor as a predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 2002;161:105-11 https://doi.org/10.1007/s00431-001-0860-1

Cited by

  1. Natriuretic Peptides in Kawasaki Disease: the Myocardial Perspective vol.3, pp.1, 2009, https://doi.org/10.3390/diagnostics3010001